Zenrelia (Ilunocitinib) Tablets for Dogs

Zenrelia contains ilunocitinib, a prescription JAK-inhibitor ingredient for dogs. Its reference label concerns itching associated with allergic dermatitis and control of atopic dermatitis, with important veterinary assessment and vaccination considerations.

A signalling-pathway medicine

Janus kinases are involved in cellular signalling associated with inflammatory responses. Ilunocitinib inhibits JAK activity. The named clinical role differs from cleaning the coat with a shampoo or applying a skin-barrier oil, even when the products share a skin-care category.

Four strength-specific tablets

The listed strengths are 4.8, 6.4, 8.5 and 15 mg. Identify the prescribed strength and tablet count. The range photograph represents separate products, not a mixed-strength box or a reason to adjust the animal’s routine.

Vaccination planning is relevant

The current referenced label warns of an inadequate immune response to vaccines during treatment. Discuss vaccination status and timing with the veterinarian, along with infections, other medicines and the animal’s health history. This clinical consideration should not be replaced with a seller’s general reassurance.

Reviewing the skin-care plan

Keep track of itching and skin changes for follow-up. The clinical assessment establishes the cause of discomfort and the role of each treatment. Zenrelia’s dog reference should not be treated as instructions for a cat or a different JAK-inhibitor product.